Lassogen

Executive Summary

Lassogen is a privately held biotechnology company pioneering a novel class of programmable therapeutics called Lassotides, which are engineered from naturally occurring lasso peptides. These molecules aim to combine the high potency and selectivity of antibodies with the stability and tissue penetration of small molecules, offering a unique modality for targeting challenging diseases. The company's initial focus is on oncology, with plans to expand into autoimmune diseases, pain, and inflammation. Founded in 2016 and based in San Diego, Lassogen is at an early stage of development, with no disclosed pipeline or funding details. Its platform has the potential to address druggable targets that are difficult to reach with conventional biologics or small molecules, leveraging the structural diversity and stability of lasso peptides. While the technology is promising, the company remains preclinical and has not yet advanced a candidate into clinical trials, resulting in a moderate conviction score.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data publication in a lead oncology program60% success
• TBDSeries A or B financing round to advance pipeline50% success
• TBDAnnouncement of a strategic partnership or licensing deal30% success